Fig. 1From: Efficacy of andrographolide in not active progressive multiple sclerosis: a prospective exploratory double-blind, parallel-group, randomized, placebo-controlled trialFlow chart. SAE serious adverse event, MRI magnetic resonance imagingBack to article page